Scaffold hopping, synthesis and structure–activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: A novel series of CB1 receptor antagonists
Jonas Boström(AstraZeneca (Sweden)), Michael Wilstermann(AstraZeneca (Sweden)), Peter J. Greasley(AstraZeneca (Sweden)), Thomas Elebring(AstraZeneca (Sweden)), Kristina Berggren(AstraZeneca (Sweden))
Cited by 66
Related Papers
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?
|Journal of Medicinal Chemistry|2015|2k
Expanding the medicinal chemistry synthetic toolbox
|Nature Reviews Drug Discovery|2018|693
Oxadiazoles in Medicinal Chemistry
|Journal of Medicinal Chemistry|2011|593
Assessing the performance of OMEGA with respect to retrieving bioactive conformations
|Journal of Molecular Graphics and Modelling|2003|315
Conformational energy penalties of protein-bound ligands
|Journal of Computer-Aided Molecular Design|1998|246